Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral arterial intervention cases in Mississippi: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (237 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 24 | 3,556 | 22% |
| 2020 | 23 | 3,220 | 25% |
| 2021 | 20 | 3,241 | 32% |
| 2022 | 22 | 2,934 | 37% |
| 2023 | 25 | 2,822 | 42% |
| 2024 | 27 | 2,361 | 46% |
| 2025 from claims | – | 2,372 2,177–2,509 | 47% |
| 2026 forecast | – | 2,364 2,080–2,728 | 48% |
| 2027 forecast | – | 2,353 2,012–2,804 | 49% |
| 2028 forecast | – | 2,342 1,954–2,868 | 50% |
| 2029 forecast | – | 2,330 1,903–2,922 | 51% |
| 2030 forecast | – | 2,317 1,856–2,969 | 52% |
Iliac, femoropopliteal, and tibial angioplasty, stenting, atherectomy. Professional codes (what the surgeon bills): CPT 37220, 37221, 37224, 37225, 37226, 37227, 37228, 37229, 37230, 37231; the hospital bills MS-DRG 252, 253, 254.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 75% of the cases CMS names in Mississippi; 13 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 3% inpatient hospital, 24% hospital outpatient, 1% surgery center, 72% office. The share outside the hospital has moved +38 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 132 | 20,074−3.1%/yr | −3.1%/yr | 8.5 | 70% | 23,800 in 2030+2.9%/yr |
| Texas | 128 | 16,813−7.6%/yr | −7.6%/yr | 7.4 | 58% | 19,600 in 2030+2.6%/yr |
| Maryland | 52 | 6,992−4.8%/yr | −4.8%/yr | 7.7 | 84% | 8,070 in 2030+2.4%/yr |
| Tennessee | 45 | 5,546−6.3%/yr | −6.3%/yr | 7.5 | 70% | 6,500 in 2030+2.7%/yr |
| North Carolina | 34 | 4,853−8.1%/yr | −8.1%/yr | 4.6 | 39% | 4,620 in 2030−0.8%/yr |
| Virginia | 30 | 3,751−7.6%/yr | −7.6%/yr | 3.5 | 43% | 5,530 in 2030+6.7%/yr |
| Georgia | 21 | 3,651−12%/yr | −12%/yr | 4.0 | 46% | 4,960 in 2030+5.3%/yr |
| Arkansas | 23 | 2,979−1.4%/yr | −1.4%/yr | 7.6 | 45% | 2,520 in 2030−2.8%/yr |
| Louisiana | 12 | 2,691−14%/yr | −14%/yr | 6.3 | 32% | 2,760 in 2030+0.4%/yr |
| South Carolina | 19 | 2,514−4.5%/yr | −4.5%/yr | 3.5 | 25% | 3,310 in 2030+4.7%/yr |
| Oklahoma | 19 | 2,386−5.2%/yr | −5.2%/yr | 4.7 | 47% | 3,400 in 2030+6.1%/yr |
| Alabama | 19 | 2,322−11%/yr | −11%/yr | 5.0 | 47% | 2,130 in 2030−1.4%/yr |
| Kentucky | 22 | 2,281−6.3%/yr | −6.3%/yr | 4.7 | 43% | 2,570 in 2030+2%/yr |
| District of Columbia | 10 | 1,226+9.5%/yr | +9.5%/yr | 18.9 | 83% | 1,830 in 2030+6.9%/yr |
| Delaware | 8 | 910−1%/yr | −1%/yr | 5.2 | 79% | 2,020 in 2030+14%/yr |
| West Virginia | 5 | 769−11%/yr | −11%/yr | 3.5 | 0% | 840 in 2030+1.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 17 | 1,861−18%/yr | −18%/yr | 5.10.9× | 36% | 1,780 in 2030−0.7%/yr |
| Superficial venous ablation | 14 | 1,432−1.3%/yr | −1.3%/yr | 3.70.6× | 88% | 1,870 in 2030+4.6%/yr |
| Thrombectomy, IVC filters & venous stents | 6 | 554+0.1%/yr | +0.1%/yr | 1.50.9× | 4% | 570 in 2030+0.6%/yr |
| Carotid revascularization | 11 | 448−8.8%/yr | −8.8%/yr | 1.20.9× | 0% | 340 in 2030−4.7%/yr |
| Aortic endografts (EVAR/TEVAR) | 2 | 121−7.9%/yr | −7.9%/yr | 0.30.7× | 0% | 130 in 2030+1.1%/yr |
Peripheral arterial intervention in every state, and its device makers · Every procedure market in Mississippi · Every state · Compare with Florida
Medtronic leads with 95% of company spending on these surgeons in 2025, +1 pts on 2024.
In 2025, 9 companies reported engagement with Mississippi’s surgeons worth $91K in consulting, speaking, meals and travel tied to these products, about $3,363 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 58 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.